Skip to main content
PMC home page
Gut logoLink to Gut
. 2001 Sep;49(3):443–453. doi: 10.1136/gut.49.3.443

Cyclooxygenase 2—implications on maintenance of gastric mucosal integrity and ulcer healing: controversial issues and perspectives

F HALTER 1, A TARNAWSKI 1, A SCHMASSMANN 1, B PESKAR 1
PMCID: PMC1728453  PMID: 11511570

Abstract

A SCHMASSMANN

Gastrointestinal Unit, University of Berne
Inselspital, Berne, Switzerland


B M PESKAR

Department of Experimental Clinical Medicine
Ruhr-University, Bochum, Germany


Cyclooxygenase (COX), the key enzyme for synthesis of prostaglandins, exists in two isoforms (COX-1 and COX-2). COX-1 is constitutively expressed in the gastrointestinal tract in large quantities and has been suggested to maintain mucosal integrity through continuous generation of prostaglandins. COX-2 is induced predominantly during inflammation. On this premise selective COX-2 inhibitors not affecting COX-1 in the gastrointestinal tract mucosa have been developed as gastrointestinal sparing anti-inflammatory drugs. They appear to be well tolerated by experimental animals and humans following acute and chronic (three or more months) administration. However, there is increasing evidence that COX-2 has a greater physiological role than merely mediating pain and inflammation. Thus gastric and intestinal lesions do not develop when COX-1 is inhibited but only when the activity of both COX-1 and COX-2 is suppressed. Selective COX-2 inhibitors delay the healing of experimental gastric ulcers to the same extent as non-COX-2 specific non-steroidal anti-inflammatory drugs (NSAIDs). Moreover, when given chronically to experimental animals, they can activate experimental colitis and cause intestinal perforation. The direct involvement of COX-2 in ulcer healing has been supported by observations that expression of COX-2 mRNA and protein is upregulated at the ulcer margin in a temporal and spatial relation to enhanced epithelial cell proliferation and increased expression of growth factors. Moreover, there is increasing evidence that upregulation of COX-2 mRNA and protein occurs during exposure of the gastric mucosa to noxious agents or to ischaemia-reperfusion. These observations support the concept that COX-2 represents (in addition to COX-1) a further line of defence for the gastrointestinal mucosa necessary for maintenance of mucosal integrity and ulcer healing.



Full Text

The Full Text of this article is available as a PDF (210.9 KB).

Figure 1  .

Figure 1  

Open in a new tab

Diagrammatic presentation of the mechanisms of non-steroidal anti-inflammatory drug (NSAID) injury to the gastrointestinal tract.

Figure 2  .

Figure 2  

Open in a new tab

(A) Ulcer healing curve assessed by video endoscopy. The data indicate mean (SEM) percentage residual ulcer size over the observation time points. Compared with placebo, omeprazole (omepr) and basic fibroblast growth factor (bFGF) treated rats showed significant reductions in ulcer diameter over days 6-15. Indomethacin (Indom) treated rats showed significantly increased ulcer diameters over days 8-22. Co-treatment with bFGF had no effect on the indomethacin induced increase in ulcer diameter. In contrast, omeprazole co-treatment reversed the deleterious effects of indomethacin. (B) Data from the same study, expressed as residual ulcer size on day 15 as a percentage of the initial ulcer size on day 1. Indomethacin plus omeprazole treated rats showed comparable ulcer diameters to placebo treated rats. *p<0.02,**p<0.005 versus placebo (from Schmassmann and colleagues45 with permission).

Figure 3  .

Figure 3  

Open in a new tab

Diagrammatic presentation of ulcer healing and factors affecting ulcer healing. Healing of the ulcer is accomplished by filling the mucosal defect with cells migrating from the ulcer margin and by connective tissue, including microvessels originating from granulation tissue. Speed and quality of ulcer healing depend, among other factors, on (1) epithelial cell migration and proliferation in the mucosal ulcer margin, (2) angiogenesis in the ulcer bed, (3) maturation and contraction of the granulation tissue in the ulcer bed, and (4) quality of remodelling of epithelial and mesenchymal structures in the late healing phase. In the intact mucosa, cyclooxygenase 1 (COX-1) is the predominant COX isoform in the gastrointestinal tract. In contrast, during wound healing, expression of cyclooxygenase 2 (COX-2), but not COX-1, is strongly increased in the repair zone of ulcer healing (from Schmassmann and colleagues46 76 with permission).

Figure 4  .

Figure 4  

Open in a new tab

(A) Time sequence of immunoreactivity of cyclooxygenase (COX)-1, COX-2, and cell proliferation (as measured by bromodeoxyuridine (BrdU) incorporation) at the ulcer margin over 21 days. (B) Ulcer healing curve assessed by video endoscopy. The data indicate mean (SEM) percentage residual ulcer size over the observation period. The specific COX-2 inhibitor L-744,337 delayed ulcer healing to the same extent as diclofenac or indomethacin when administered at doses of similar anti-inflammatory potency (as tested in the carrageenan paw model) (from Schmassmann and colleagues76 with permission).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aalykke C., Lauritsen J. M., Hallas J., Reinholdt S., Krogfelt K., Lauritsen K. Helicobacter pylori and risk of ulcer bleeding among users of nonsteroidal anti-inflammatory drugs: a case-control study. Gastroenterology. 1999 Jun;116(6):1305–1309. doi: 10.1016/s0016-5085(99)70494-4. [DOI] [PubMed] [Google Scholar]
  2. Agrawal N. M., Roth S., Graham D. Y., White R. H., Germain B., Brown J. A., Stromatt S. C. Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer. A randomized, controlled trial. Ann Intern Med. 1991 Aug 1;115(3):195–200. doi: 10.7326/0003-4819-115-3-195. [DOI] [PubMed] [Google Scholar]
  3. Asako H., Kubes P., Wallace J., Gaginella T., Wolf R. E., Granger D. N. Indomethacin-induced leukocyte adhesion in mesenteric venules: role of lipoxygenase products. Am J Physiol. 1992 May;262(5 Pt 1):G903–G908. doi: 10.1152/ajpgi.1992.262.5.G903. [DOI] [PubMed] [Google Scholar]
  4. Asako H., Kubes P., Wallace J., Wolf R. E., Granger D. N. Modulation of leukocyte adhesion in rat mesenteric venules by aspirin and salicylate. Gastroenterology. 1992 Jul;103(1):146–152. doi: 10.1016/0016-5085(92)91107-f. [DOI] [PubMed] [Google Scholar]
  5. Bardhan K. D., Bjarnason I., Scott D. L., Griffin W. M., Fenn G. C., Shield M. J., Morant S. V. The prevention and healing of acute non-steroidal anti-inflammatory drug-associated gastroduodenal mucosal damage by misoprostol. Br J Rheumatol. 1993 Nov;32(11):990–995. doi: 10.1093/rheumatology/32.11.990. [DOI] [PubMed] [Google Scholar]
  6. Bellary S. V., Isaacs P. E., Lee F. I. Upper gastrointestinal lesions in elderly patients presenting for endoscopy: relevance of NSAID usage. Am J Gastroenterol. 1991 Aug;86(8):961–964. [PubMed] [Google Scholar]
  7. Bjarnason I., Hayllar J., MacPherson A. J., Russell A. S. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology. 1993 Jun;104(6):1832–1847. doi: 10.1016/0016-5085(93)90667-2. [DOI] [PubMed] [Google Scholar]
  8. Boolbol S. K., Dannenberg A. J., Chadburn A., Martucci C., Guo X. J., Ramonetti J. T., Abreu-Goris M., Newmark H. L., Lipkin M. L., DeCosse J. J. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res. 1996 Jun 1;56(11):2556–2560. [PubMed] [Google Scholar]
  9. Brown J. F., Hanson P. J., Whittle B. J. Nitric oxide donors increase mucus gel thickness in rat stomach. Eur J Pharmacol. 1992 Nov 13;223(1):103–104. doi: 10.1016/0014-2999(92)90824-n. [DOI] [PubMed] [Google Scholar]
  10. Chan C. C., Boyce S., Brideau C., Charleson S., Cromlish W., Ethier D., Evans J., Ford-Hutchinson A. W., Forrest M. J., Gauthier J. Y. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther. 1999 Aug;290(2):551–560. [PubMed] [Google Scholar]
  11. Chan C. C., Boyce S., Brideau C., Ford-Hutchinson A. W., Gordon R., Guay D., Hill R. G., Li C. S., Mancini J., Penneton M. Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J Pharmacol Exp Ther. 1995 Sep;274(3):1531–1537. [PubMed] [Google Scholar]
  12. Chan F. K., Sung J. J., Chung S. C., To K. F., Yung M. Y., Leung V. K., Lee Y. T., Chan C. S., Li E. K., Woo J. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet. 1997 Oct 4;350(9083):975–979. doi: 10.1016/s0140-6736(97)04523-6. [DOI] [PubMed] [Google Scholar]
  13. Cheatum D. E., Arvanitakis C., Gumpel M., Stead H., Geis G. S. An endoscopic study of gastroduodenal lesions induced by nonsteroidal anti-inflammatory drugs. Clin Ther. 1999 Jun;21(6):992–1003. doi: 10.1016/s0149-2918(99)80020-4. [DOI] [PubMed] [Google Scholar]
  14. Cryer B., Dubois A. The advent of highly selective inhibitors of cyclooxygenase--a review. Prostaglandins Other Lipid Mediat. 1998 Aug;56(5-6):341–361. doi: 10.1016/s0090-6980(98)00064-1. [DOI] [PubMed] [Google Scholar]
  15. Davies N. M., Røseth A. G., Appleyard C. B., McKnight W., Del Soldato P., Calignano A., Cirino G., Wallace J. L. NO-naproxen vs. naproxen: ulcerogenic, analgesic and anti-inflammatory effects. Aliment Pharmacol Ther. 1997 Feb;11(1):69–79. doi: 10.1046/j.1365-2036.1997.115286000.x. [DOI] [PubMed] [Google Scholar]
  16. Davies N. M., Sharkey K. A., Asfaha S., Macnaughton W. K., Wallace J. L. Aspirin causes rapid up-regulation of cyclo-oxygenase-2 expression in the stomach of rats. Aliment Pharmacol Ther. 1997 Dec;11(6):1101–1108. doi: 10.1046/j.1365-2036.1997.00247.x. [DOI] [PubMed] [Google Scholar]
  17. Eberhart C. E., Coffey R. J., Radhika A., Giardiello F. M., Ferrenbach S., DuBois R. N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994 Oct;107(4):1183–1188. doi: 10.1016/0016-5085(94)90246-1. [DOI] [PubMed] [Google Scholar]
  18. Ehrlich K., Plate S., Stroff T., Gretzer B., Respondek M., Peskar B. M. Peptidergic and cholinergic neurons and mediators in peptone-induced gastroprotection: role of cyclooxygenase-2. Am J Physiol. 1998 May;274(5 Pt 1):G955–G964. doi: 10.1152/ajpgi.1998.274.5.G955. [DOI] [PubMed] [Google Scholar]
  19. Ehsanullah R. S., Page M. C., Tildesley G., Wood J. R. Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine. BMJ. 1988 Oct 22;297(6655):1017–1021. doi: 10.1136/bmj.297.6655.1017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. El-Omar E. M., Oien K., El-Nujumi A., Gillen D., Wirz A., Dahill S., Williams C., Ardill J. E., McColl K. E. Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology. 1997 Jul;113(1):15–24. doi: 10.1016/s0016-5085(97)70075-1. [DOI] [PubMed] [Google Scholar]
  21. Elliott S. L., Ferris R. J., Giraud A. S., Cook G. A., Skeljo M. V., Yeomans N. D. Indomethacin damage to rat gastric mucosa is markedly dependent on luminal pH. Clin Exp Pharmacol Physiol. 1996 May;23(5):432–434. doi: 10.1111/j.1440-1681.1996.tb02754.x. [DOI] [PubMed] [Google Scholar]
  22. Elliott S. N., McKnight W., Cirino G., Wallace J. L. A nitric oxide-releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats. Gastroenterology. 1995 Aug;109(2):524–530. doi: 10.1016/0016-5085(95)90341-0. [DOI] [PubMed] [Google Scholar]
  23. Emery P., Zeidler H., Kvien T. K., Guslandi M., Naudin R., Stead H., Verburg K. M., Isakson P. C., Hubbard R. C., Geis G. S. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet. 1999 Dec 18;354(9196):2106–2111. doi: 10.1016/S0140-6736(99)02332-6. [DOI] [PubMed] [Google Scholar]
  24. Ferraz J. G., Sharkey K. A., Reuter B. K., Asfaha S., Tigley A. W., Brown M. L., McKnight W., Wallace J. L. Induction of cyclooxygenase 1 and 2 in the rat stomach during endotoxemia: role in resistance to damage. Gastroenterology. 1997 Jul;113(1):195–204. doi: 10.1016/s0016-5085(97)70095-7. [DOI] [PubMed] [Google Scholar]
  25. Franco L., Talamini G., Carra G., Doria D. Expression of COX-1, COX-2, and inducible nitric oxide synthase protein in human gastric antrum with Helicobacter pylori infection. Prostaglandins Other Lipid Mediat. 1999 Aug;58(1):9–17. doi: 10.1016/s0090-6980(99)00020-9. [DOI] [PubMed] [Google Scholar]
  26. Fu S., Ramanujam K. S., Wong A., Fantry G. T., Drachenberg C. B., James S. P., Meltzer S. J., Wilson K. T. Increased expression and cellular localization of inducible nitric oxide synthase and cyclooxygenase 2 in Helicobacter pylori gastritis. Gastroenterology. 1999 Jun;116(6):1319–1329. doi: 10.1016/s0016-5085(99)70496-8. [DOI] [PubMed] [Google Scholar]
  27. Fukatsu K., Saito H., Han I., Furukawa S., Lin M. T., Matsuda T., Ikeda S., Inoue T., Yasuhara H., Muto T. Nitric oxide donor decreases neutrophil adhesion in both lung and peritoneum during peritonitis. J Surg Res. 1998 Feb 1;74(2):119–124. doi: 10.1006/jsre.1997.5234. [DOI] [PubMed] [Google Scholar]
  28. Gana T. J., Huhlewych R., Koo J. Focal gastric mucosal blood flow in aspirin-induced ulceration. Ann Surg. 1987 Apr;205(4):399–403. doi: 10.1097/00000658-198704000-00010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Geis G. S., Stead H., Wallemark C. B., Nicholson P. A. Prevalence of mucosal lesions in the stomach and duodenum due to chronic use of NSAID in patients with rheumatoid arthritis or osteoarthritis, and interim report on prevention by misoprostol of diclofenac associated lesions. J Rheumatol Suppl. 1991 Mar;28:11–14. [PubMed] [Google Scholar]
  30. Giardiello F. M., Hamilton S. R., Krush A. J., Piantadosi S., Hylind L. M., Celano P., Booker S. V., Robinson C. R., Offerhaus G. J. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med. 1993 May 6;328(18):1313–1316. doi: 10.1056/NEJM199305063281805. [DOI] [PubMed] [Google Scholar]
  31. Gidday J. M., Park T. S., Shah A. R., Gonzales E. R. Modulation of basal and postischemic leukocyte-endothelial adherence by nitric oxide. Stroke. 1998 Jul;29(7):1423–1430. doi: 10.1161/01.str.29.7.1423. [DOI] [PubMed] [Google Scholar]
  32. Goddard P. J., Hills B. A., Lichtenberger L. M. Does aspirin damage canine gastric mucosa by reducing its surface hydrophobicity? Am J Physiol. 1987 Mar;252(3 Pt 1):G421–G430. doi: 10.1152/ajpgi.1987.252.3.G421. [DOI] [PubMed] [Google Scholar]
  33. Graham D. Y., Smith J. L., Spjut H. J., Torres E. Gastric adaptation. Studies in humans during continuous aspirin administration. Gastroenterology. 1988 Aug;95(2):327–333. [PubMed] [Google Scholar]
  34. Gretzer B., Ehrlich K., Maricic N., Lambrecht N., Respondek M., Peskar B. M. Selective cyclo-oxygenase-2 inhibitors and their influence on the protective effect of a mild irritant in the rat stomach. Br J Pharmacol. 1998 Mar;123(5):927–935. doi: 10.1038/sj.bjp.0701673. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Gretzer B., Maricic N., Respondek M., Schuligoi R., Peskar B. M. Effects of specific inhibition of cyclo-oxygenase-1 and cyclo-oxygenase-2 in the rat stomach with normal mucosa and after acid challenge. Br J Pharmacol. 2001 Apr;132(7):1565–1573. doi: 10.1038/sj.bjp.0703955. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Gut A., Halter F., Ruchti C. Nichtsteroidale Antirheumatika und Azetylsalizylsäure: Nebenwirkungen distal des Duodenums. Schweiz Med Wochenschr. 1996 Apr 13;126(15):616–625. [PubMed] [Google Scholar]
  37. HOGBEN C. A., SCHANKER L. S., TOCCO D. J., BRODIE B. B. Absorption of drugs from the stomach. II. The human. J Pharmacol Exp Ther. 1957 Aug;120(4):540–545. [PubMed] [Google Scholar]
  38. Halter F., Peskar B., Rainsford K. D., Schmassmann A. Cytoprotection and healing: two unequal brethren. Inflammopharmacology. 1997;5(4):407–414. doi: 10.1007/s10787-997-0036-3. [DOI] [PubMed] [Google Scholar]
  39. Hamilton L. C., Mitchell J. A., Tomlinson A. M., Warner T. D. Synergy between cyclo-oxygenase-2 induction and arachidonic acid supply in vivo: consequences for nonsteroidal antiinflammatory drug efficacy. FASEB J. 1999 Feb;13(2):245–251. doi: 10.1096/fasebj.13.2.245. [DOI] [PubMed] [Google Scholar]
  40. Harris R. C., McKanna J. A., Akai Y., Jacobson H. R., Dubois R. N., Breyer M. D. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest. 1994 Dec;94(6):2504–2510. doi: 10.1172/JCI117620. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Harris R. E., Alshafie G. A., Abou-Issa H., Seibert K. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res. 2000 Apr 15;60(8):2101–2103. [PubMed] [Google Scholar]
  42. Hawkey C. J. COX-2 inhibitors. Lancet. 1999 Jan 23;353(9149):307–314. doi: 10.1016/s0140-6736(98)12154-2. [DOI] [PubMed] [Google Scholar]
  43. Hawkey C. J. Non-steroidal anti-inflammatory drugs and peptic ulcers. BMJ. 1990 Feb 3;300(6720):278–284. doi: 10.1136/bmj.300.6720.278. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Hawkey C. J., Tulassay Z., Szczepanski L., van Rensburg C. J., Filipowicz-Sosnowska A., Lanas A., Wason C. M., Peacock R. A., Gillon K. R. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. Lancet. 1998 Sep 26;352(9133):1016–1021. doi: 10.1016/s0140-6736(98)04206-8. [DOI] [PubMed] [Google Scholar]
  45. Hawkey C. J., Walt R. P. Prostaglandins for peptic ulcer: a promise unfulfilled. Lancet. 1986 Nov 8;2(8515):1084–1087. doi: 10.1016/s0140-6736(86)90478-2. [DOI] [PubMed] [Google Scholar]
  46. Hawkey C. J., Yeomans N. D., Gillon K. Helicobacter pylori, NSAIDs, and peptic ulcers. Lancet. 1998 Jan 3;351(9095):61–62. doi: 10.1016/s0140-6736(05)78065-x. [DOI] [PubMed] [Google Scholar]
  47. Hawkey C., Laine L., Simon T., Beaulieu A., Maldonado-Cocco J., Acevedo E., Shahane A., Quan H., Bolognese J., Mortensen E. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group. Arthritis Rheum. 2000 Feb;43(2):370–377. doi: 10.1002/1529-0131(200002)43:2<370::AID-ANR17>3.0.CO;2-D. [DOI] [PubMed] [Google Scholar]
  48. Hennekens C. H. Update on aspirin in the treatment and prevention of cardiovascular disease. Am Heart J. 1999 Apr;137(4 Pt 2):S9–S13. doi: 10.1016/s0002-8703(99)70391-1. [DOI] [PubMed] [Google Scholar]
  49. Henry D., Lim L. L., Garcia Rodriguez L. A., Perez Gutthann S., Carson J. L., Griffin M., Savage R., Logan R., Moride Y., Hawkey C. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ. 1996 Jun 22;312(7046):1563–1566. doi: 10.1136/bmj.312.7046.1563. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Hirose H., Takeuchi K., Okabe S. Effect of indomethacin on gastric mucosal blood flow around acetic acid-induced gastric ulcers in rats. Gastroenterology. 1991 May;100(5 Pt 1):1259–1265. [PubMed] [Google Scholar]
  51. Hudson N., Balsitis M., Everitt S., Hawkey C. J. Enhanced gastric mucosal leukotriene B4 synthesis in patients taking non-steroidal anti-inflammatory drugs. Gut. 1993 Jun;34(6):742–747. doi: 10.1136/gut.34.6.742. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Inauen W., Wyss P. A., Kayser S., Baumgartner A., Schürer-Maly C. C., Koelz H. R., Halter F. Influence of prostaglandins, omeprazole, and indomethacin on healing of experimental gastric ulcers in the rat. Gastroenterology. 1988 Sep;95(3):636–641. doi: 10.1016/s0016-5085(88)80009-x. [DOI] [PubMed] [Google Scholar]
  53. Iseki S. Immunocytochemical localization of cyclooxygenase-1 and cyclooxygenase-2 in the rat stomach. Histochem J. 1995 Apr;27(4):323–328. doi: 10.1007/BF00398975. [DOI] [PubMed] [Google Scholar]
  54. Jackson L. M., Wu K. C., Mahida Y. R., Jenkins D., Hawkey C. J. Cyclooxygenase (COX) 1 and 2 in normal, inflamed, and ulcerated human gastric mucosa. Gut. 2000 Dec;47(6):762–770. doi: 10.1136/gut.47.6.762. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Jacoby R. F., Marshall D. J., Newton M. A., Novakovic K., Tutsch K., Cole C. E., Lubet R. A., Kelloff G. J., Verma A., Moser A. R. Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res. 1996 Feb 15;56(4):710–714. [PubMed] [Google Scholar]
  56. Jones M. K., Sasaki E., Halter F., Pai R., Nakamura T., Arakawa T., Kuroki T., Tarnawski A. S. HGF triggers activation of the COX-2 gene in rat gastric epithelial cells: action mediated through the ERK2 signaling pathway. FASEB J. 1999 Dec;13(15):2186–2194. doi: 10.1096/fasebj.13.15.2186. [DOI] [PubMed] [Google Scholar]
  57. Jones M. K., Wang H., Peskar B. M., Levin E., Itani R. M., Sarfeh I. J., Tarnawski A. S. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med. 1999 Dec;5(12):1418–1423. doi: 10.1038/70995. [DOI] [PubMed] [Google Scholar]
  58. Kirtikara K., Morham S. G., Raghow R., Laulederkind S. J., Kanekura T., Goorha S., Ballou L. R. Compensatory prostaglandin E2 biosynthesis in cyclooxygenase 1 or 2 null cells. J Exp Med. 1998 Feb 16;187(4):517–523. doi: 10.1084/jem.187.4.517. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Kishimoto Y., Wada K., Nakamoto K., Kawasaki H., Hasegawa J. Levels of cyclooxygenase-1 and -2 mRNA expression at various stages of acute gastric injury induced by ischemia-reperfusion in rats. Arch Biochem Biophys. 1998 Apr 1;352(1):153–157. doi: 10.1006/abbi.1997.0572. [DOI] [PubMed] [Google Scholar]
  60. Konturek J. W., Dembinski A., Konturek S. J., Stachura J., Domschke W. Infection of Helicobacter pylori in gastric adaptation to continued administration of aspirin in humans. Gastroenterology. 1998 Feb;114(2):245–255. doi: 10.1016/s0016-5085(98)70474-3. [DOI] [PubMed] [Google Scholar]
  61. Kubes P. Nitric oxide modulates epithelial permeability in the feline small intestine. Am J Physiol. 1992 Jun;262(6 Pt 1):G1138–G1142. doi: 10.1152/ajpgi.1992.262.6.G1138. [DOI] [PubMed] [Google Scholar]
  62. Kubes P., Suzuki M., Granger D. N. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):4651–4655. doi: 10.1073/pnas.88.11.4651. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Kujubu D. A., Fletcher B. S., Varnum B. C., Lim R. W., Herschman H. R. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem. 1991 Jul 15;266(20):12866–12872. [PubMed] [Google Scholar]
  64. Laine L., Harper S., Simon T., Bath R., Johanson J., Schwartz H., Stern S., Quan H., Bolognese J. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. Gastroenterology. 1999 Oct;117(4):776–783. doi: 10.1016/s0016-5085(99)70334-3. [DOI] [PubMed] [Google Scholar]
  65. Langenbach R., Morham S. G., Tiano H. F., Loftin C. D., Ghanayem B. I., Chulada P. C., Mahler J. F., Lee C. A., Goulding E. H., Kluckman K. D. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell. 1995 Nov 3;83(3):483–492. doi: 10.1016/0092-8674(95)90126-4. [DOI] [PubMed] [Google Scholar]
  66. Langman M. J., Weil J., Wainwright P., Lawson D. H., Rawlins M. D., Logan R. F., Murphy M., Vessey M. P., Colin-Jones D. G. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet. 1994 Apr 30;343(8905):1075–1078. doi: 10.1016/s0140-6736(94)90185-6. [DOI] [PubMed] [Google Scholar]
  67. Lanza F. L. A review of gastric ulcer and gastroduodenal injury in normal volunteers receiving aspirin and other non-steroidal anti-inflammatory drugs. Scand J Gastroenterol Suppl. 1989;163:24–31. doi: 10.3109/00365528909091171. [DOI] [PubMed] [Google Scholar]
  68. Lee M., Aldred K., Lee E., Feldman M. Aspirin-induced acute gastric mucosal injury is a neutrophil-dependent process in rats. Am J Physiol. 1992 Dec;263(6 Pt 1):G920–G926. doi: 10.1152/ajpgi.1992.263.6.G920. [DOI] [PubMed] [Google Scholar]
  69. Lesch C. A., Gilbertsen R. B., Song Y., Dyer R. D., Schrier D., Kraus E. R., Sanchez B., Guglietta A. Effects of novel anti-inflammatory compounds on healing of acetic acid-induced gastric ulcer in rats. J Pharmacol Exp Ther. 1998 Oct;287(1):301–306. [PubMed] [Google Scholar]
  70. Levi S., Goodlad R. A., Lee C. Y., Stamp G., Walport M. J., Wright N. A., Hodgson H. J. Inhibitory effect of non-steroidal anti-inflammatory drugs on mucosal cell proliferation associated with gastric ulcer healing. Lancet. 1990 Oct 6;336(8719):840–843. doi: 10.1016/0140-6736(90)92341-e. [DOI] [PubMed] [Google Scholar]
  71. Lichtenberger L. M. The hydrophobic barrier properties of gastrointestinal mucus. Annu Rev Physiol. 1995;57:565–583. doi: 10.1146/annurev.ph.57.030195.003025. [DOI] [PubMed] [Google Scholar]
  72. Lichtenberger L. M., Wang Z. M., Romero J. J., Ulloa C., Perez J. C., Giraud M. N., Barreto J. C. Non-steroidal anti-inflammatory drugs (NSAIDs) associate with zwitterionic phospholipids: insight into the mechanism and reversal of NSAID-induced gastrointestinal injury. Nat Med. 1995 Feb;1(2):154–158. doi: 10.1038/nm0295-154. [DOI] [PubMed] [Google Scholar]
  73. Mahmud T., Scott D. L., Bjarnason I. A unifying hypothesis for the mechanism of NSAID related gastrointestinal toxicity. Ann Rheum Dis. 1996 Apr;55(4):211–213. doi: 10.1136/ard.55.4.211. [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Mandell B. F. COX 2-selective NSAIDs: biology, promises, and concerns. Cleve Clin J Med. 1999 May;66(5):285–292. doi: 10.3949/ccjm.66.5.285. [DOI] [PubMed] [Google Scholar]
  75. Maricic N., Ehrlich K., Gretzer B., Schuligoi R., Respondek M., Peskar B. M. Selective cyclo-oxygenase-2 inhibitors aggravate ischaemia-reperfusion injury in the rat stomach. Br J Pharmacol. 1999 Dec;128(8):1659–1666. doi: 10.1038/sj.bjp.0702966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. May G. R., Crook P., Moore P. K., Page C. P. The role of nitric oxide as an endogenous regulator of platelet and neutrophil activation within the pulmonary circulation of the rabbit. Br J Pharmacol. 1991 Mar;102(3):759–763. doi: 10.1111/j.1476-5381.1991.tb12246.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. McAdam B. F., Catella-Lawson F., Mardini I. A., Kapoor S., Lawson J. A., FitzGerald G. A. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A. 1999 Jan 5;96(1):272–277. doi: 10.1073/pnas.96.1.272. [DOI] [PMC free article] [PubMed] [Google Scholar]
  78. McCarthy C. J., Crofford L. J., Greenson J., Scheiman J. M. Cyclooxygenase-2 expression in gastric antral mucosa before and after eradication of Helicobacter pylori infection. Am J Gastroenterol. 1999 May;94(5):1218–1223. doi: 10.1111/j.1572-0241.1999.01070.x. [DOI] [PubMed] [Google Scholar]
  79. Miller J. L. Celecoxib approved as NSAID with some concessions on class warning. Am J Health Syst Pharm. 1999 Mar 1;56(5):403–403. doi: 10.1093/ajhp/56.5.403. [DOI] [PubMed] [Google Scholar]
  80. Mitchell J. A., Akarasereenont P., Thiemermann C., Flower R. J., Vane J. R. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11693–11697. doi: 10.1073/pnas.90.24.11693. [DOI] [PMC free article] [PubMed] [Google Scholar]
  81. Mitchell J. A., Evans T. W. Cyclooxygenase-2 as a therapeutic target. Inflamm Res. 1998 Oct;47 (Suppl 2):S88–S92. doi: 10.1007/s000110050287. [DOI] [PubMed] [Google Scholar]
  82. Mizuno H., Sakamoto C., Matsuda K., Wada K., Uchida T., Noguchi H., Akamatsu T., Kasuga M. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology. 1997 Feb;112(2):387–397. doi: 10.1053/gast.1997.v112.pm9024292. [DOI] [PubMed] [Google Scholar]
  83. Mohammed S., Croom D. W., 2nd Gastropathy due to celecoxib, a cyclooxygenase-2 inhibitor. N Engl J Med. 1999 Jun 24;340(25):2005–2006. doi: 10.1056/NEJM199906243402516. [DOI] [PubMed] [Google Scholar]
  84. Morham S. G., Langenbach R., Loftin C. D., Tiano H. F., Vouloumanos N., Jennette J. C., Mahler J. F., Kluckman K. D., Ledford A., Lee C. A. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell. 1995 Nov 3;83(3):473–482. doi: 10.1016/0092-8674(95)90125-6. [DOI] [PubMed] [Google Scholar]
  85. Newberry R. D., Stenson W. F., Lorenz R. G. Cyclooxygenase-2-dependent arachidonic acid metabolites are essential modulators of the intestinal immune response to dietary antigen. Nat Med. 1999 Aug;5(8):900–906. doi: 10.1038/11341. [DOI] [PubMed] [Google Scholar]
  86. O'Neill G. P., Ford-Hutchinson A. W. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett. 1993 Sep 13;330(2):156–160. doi: 10.1016/0014-5793(93)80263-t. [DOI] [PubMed] [Google Scholar]
  87. Oshima M., Dinchuk J. E., Kargman S. L., Oshima H., Hancock B., Kwong E., Trzaskos J. M., Evans J. F., Taketo M. M. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell. 1996 Nov 29;87(5):803–809. doi: 10.1016/s0092-8674(00)81988-1. [DOI] [PubMed] [Google Scholar]
  88. Palmer H. COX-2 selectivity and lack of gastrointestinal toxicity: true, true and unrelated. Gastroenterology. 2000 Mar;118(3):640–641. doi: 10.1016/s0016-5085(00)70281-2. [DOI] [PubMed] [Google Scholar]
  89. Pantoflickova D., Blum A. L., Bercik P. Omeprazole: Helicobacter pylori makes thee greater yet. Gut. 1999 Apr;44(4):448–449. doi: 10.1136/gut.44.4.448. [DOI] [PMC free article] [PubMed] [Google Scholar]
  90. Pique J. M., Esplugues J. V., Whittle B. J. Endogenous nitric oxide as a mediator of gastric mucosal vasodilatation during acid secretion. Gastroenterology. 1992 Jan;102(1):168–174. doi: 10.1016/0016-5085(92)91797-8. [DOI] [PubMed] [Google Scholar]
  91. Plummer S. M., Hall M., Faux S. P. Oxidation and genotoxicity of fecapentaene-12 are potentiated by prostaglandin H synthase. Carcinogenesis. 1995 May;16(5):1023–1028. doi: 10.1093/carcin/16.5.1023. [DOI] [PubMed] [Google Scholar]
  92. Reuter B. K., Asfaha S., Buret A., Sharkey K. A., Wallace J. L. Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2. J Clin Invest. 1996 Nov 1;98(9):2076–2085. doi: 10.1172/JCI119013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  93. Robert A., Nezamis J. E., Lancaster C., Hanchar A. J. Cytoprotection by prostaglandins in rats. Prevention of gastric necrosis produced by alcohol, HCl, NaOH, hypertonic NaCl, and thermal injury. Gastroenterology. 1979 Sep;77(3):433–443. [PubMed] [Google Scholar]
  94. Romano M., Ricci V., Memoli A., Tuccillo C., Di Popolo A., Sommi P., Acquaviva A. M., Del Vecchio Blanco C., Bruni C. B., Zarrilli R. Helicobacter pylori up-regulates cyclooxygenase-2 mRNA expression and prostaglandin E2 synthesis in MKN 28 gastric mucosal cells in vitro. J Biol Chem. 1998 Oct 30;273(44):28560–28563. doi: 10.1074/jbc.273.44.28560. [DOI] [PubMed] [Google Scholar]
  95. Santolaria S., Lanas A., Benito R., Pérez-Aisa M. f., Montoro M., Sainz R. Helicobacter pylori infection is a protective factor for bleeding gastric ulcers but not for bleeding duodenal ulcers in NSAID users. Aliment Pharmacol Ther. 1999 Nov;13(11):1511–1518. doi: 10.1046/j.1365-2036.1999.00631.x. [DOI] [PubMed] [Google Scholar]
  96. Sarosiek J., Slomiany A., Slomiany B. L. Evidence for weakening of gastric mucus integrity by Campylobacter pylori. Scand J Gastroenterol. 1988 Jun;23(5):585–590. doi: 10.3109/00365528809093916. [DOI] [PubMed] [Google Scholar]
  97. Sasaki E., Pai R., Halter F., Komurasaki T., Arakawa T., Kobayashi K., Kuroki T., Tarnawski A. S. Induction of cyclooxygenase-2 in a rat gastric epithelial cell line by epiregulin and basic fibroblast growth factor. J Clin Gastroenterol. 1998;27 (Suppl 1):S21–S27. doi: 10.1097/00004836-199800001-00005. [DOI] [PubMed] [Google Scholar]
  98. Sawaoka H., Kawano S., Tsuji S., Tsuji M., Sun W., Gunawan E. S., Hori M. Helicobacter pylori infection induces cyclooxygenase-2 expression in human gastric mucosa. Prostaglandins Leukot Essent Fatty Acids. 1998 Nov;59(5):313–316. doi: 10.1016/s0952-3278(98)90079-5. [DOI] [PubMed] [Google Scholar]
  99. Sawaoka H., Tsuji S., Tsujii M., Gunawan E. S., Nakama A., Takei Y., Nagano K., Matsui H., Kawano S., Hori M. Expression of the cyclooxygenase-2 gene in gastric epithelium. J Clin Gastroenterol. 1997;25 (Suppl 1):S105–S110. doi: 10.1097/00004836-199700001-00018. [DOI] [PubMed] [Google Scholar]
  100. Schmassmann A., Peskar B. M., Stettler C., Netzer P., Stroff T., Flogerzi B., Halter F. Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastro-intestinal ulcer models in rats. Br J Pharmacol. 1998 Mar;123(5):795–804. doi: 10.1038/sj.bjp.0701672. [DOI] [PMC free article] [PubMed] [Google Scholar]
  101. Schmassmann A., Tarnawski A., Peskar B. M., Varga L., Flogerzi B., Halter F. Influence of acid and angiogenesis on kinetics of gastric ulcer healing in rats: interaction with indomethacin. Am J Physiol. 1995 Feb;268(2 Pt 1):G276–G285. doi: 10.1152/ajpgi.1995.268.2.G276. [DOI] [PubMed] [Google Scholar]
  102. Shirvani V. N., Ouatu-Lascar R., Kaur B. S., Omary M. B., Triadafilopoulos G. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure. Gastroenterology. 2000 Mar;118(3):487–496. doi: 10.1016/s0016-5085(00)70254-x. [DOI] [PubMed] [Google Scholar]
  103. Silverstein F. E., Faich G., Goldstein J. L., Simon L. S., Pincus T., Whelton A., Makuch R., Eisen G., Agrawal N. M., Stenson W. F. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000 Sep 13;284(10):1247–1255. doi: 10.1001/jama.284.10.1247. [DOI] [PubMed] [Google Scholar]
  104. Simon L. S., Weaver A. L., Graham D. Y., Kivitz A. J., Lipsky P. E., Hubbard R. C., Isakson P. C., Verburg K. M., Yu S. S., Zhao W. W. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA. 1999 Nov 24;282(20):1921–1928. doi: 10.1001/jama.282.20.1921. [DOI] [PubMed] [Google Scholar]
  105. Singh G., Ramey D. R., Morfeld D., Shi H., Hatoum H. T., Fries J. F. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. Arch Intern Med. 1996 Jul 22;156(14):1530–1536. [PubMed] [Google Scholar]
  106. Sirko S. P., Schindler R., Doyle M. J., Weisman S. M., Dinarello C. A. Transcription, translation and secretion of interleukin 1 and tumor necrosis factor: effects of tebufelone, a dual cyclooxygenase/5-lipoxygenase inhibitor. Eur J Immunol. 1991 Feb;21(2):243–250. doi: 10.1002/eji.1830210202. [DOI] [PubMed] [Google Scholar]
  107. Somasundaram S., Sigthorsson G., Simpson R. J., Watts J., Jacob M., Tavares I. A., Rafi S., Roseth A., Foster R., Price A. B. Uncoupling of intestinal mitochondrial oxidative phosphorylation and inhibition of cyclooxygenase are required for the development of NSAID-enteropathy in the rat. Aliment Pharmacol Ther. 2000 May;14(5):639–650. doi: 10.1046/j.1365-2036.2000.00723.x. [DOI] [PubMed] [Google Scholar]
  108. Stadler P., Armstrong D., Margalith D., Saraga E., Stolte M., Lualdi P., Mautone G., Blum A. L. Diclofenac delays healing of gastroduodenal mucosal lesions. Double-blind, placebo-controlled endoscopic study in healthy volunteers. Dig Dis Sci. 1991 May;36(5):594–600. doi: 10.1007/BF01297025. [DOI] [PubMed] [Google Scholar]
  109. Stewart W. F., Kawas C., Corrada M., Metter E. J. Risk of Alzheimer's disease and duration of NSAID use. Neurology. 1997 Mar;48(3):626–632. doi: 10.1212/wnl.48.3.626. [DOI] [PubMed] [Google Scholar]
  110. Taha A. S., Angerson W., Nakshabendi I., Beekman H., Morran C., Sturrock R. D., Russell R. I. Gastric and duodenal mucosal blood flow in patients receiving non-steroidal anti-inflammatory drugs--influence of age, smoking, ulceration and Helicobacter pylori. Aliment Pharmacol Ther. 1993 Feb;7(1):41–45. doi: 10.1111/j.1365-2036.1993.tb00067.x. [DOI] [PubMed] [Google Scholar]
  111. Taha A. S., Dahill S., Morran C., Hudson N., Hawkey C. J., Lee F. D., Sturrock R. D., Russell R. I. Neutrophils, Helicobacter pylori, and nonsteroidal anti-inflammatory drug ulcers. Gastroenterology. 1999 Feb;116(2):254–258. doi: 10.1016/s0016-5085(99)70120-4. [DOI] [PubMed] [Google Scholar]
  112. Taha A. S., Sturrock R. D., Russell R. I. Mucosal erosions in longterm non-steroidal anti-inflammatory drug users: predisposition to ulceration and relation to Helicobacter pylori. Gut. 1995 Mar;36(3):334–336. doi: 10.1136/gut.36.3.334. [DOI] [PMC free article] [PubMed] [Google Scholar]
  113. Takahashi S., Shigeta J., Inoue H., Tanabe T., Okabe S. Localization of cyclooxygenase-2 and regulation of its mRNA expression in gastric ulcers in rats. Am J Physiol. 1998 Nov;275(5 Pt 1):G1137–G1145. doi: 10.1152/ajpgi.1998.275.5.G1137. [DOI] [PubMed] [Google Scholar]
  114. Tarnawski A., Brzozowski T., Sarfeh I. J., Krause W. J., Ulich T. R., Gergely H., Hollander D. Prostaglandin protection of human isolated gastric glands against indomethacin and ethanol injury. Evidence for direct cellular action of prostaglandin. J Clin Invest. 1988 Apr;81(4):1081–1089. doi: 10.1172/JCI113420. [DOI] [PMC free article] [PubMed] [Google Scholar]
  115. Tarnawski A., Stachura J., Gergely H., Hollander D. Gastric microvascular endothelium: a major target for aspirin-induced injury and arachidonic acid protection. An ultrastructural analysis in the rat. Eur J Clin Invest. 1990 Aug;20(4):432–440. doi: 10.1111/j.1365-2362.1990.tb01881.x. [DOI] [PubMed] [Google Scholar]
  116. Tepperman B. L., Whittle B. J. Endogenous nitric oxide and sensory neuropeptides interact in the modulation of the rat gastric microcirculation. Br J Pharmacol. 1992 Jan;105(1):171–175. doi: 10.1111/j.1476-5381.1992.tb14230.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  117. Ukawa H., Yamakuni H., Kato S., Takeuchi K. Effects of cyclooxygenase-2 selective and nitric oxide-releasing nonsteroidal antiinflammatory drugs on mucosal ulcerogenic and healing responses of the stomach. Dig Dis Sci. 1998 Sep;43(9):2003–2011. doi: 10.1023/a:1018846912032. [DOI] [PubMed] [Google Scholar]
  118. Vaananen P. M., Meddings J. B., Wallace J. L. Role of oxygen-derived free radicals in indomethacin-induced gastric injury. Am J Physiol. 1991 Sep;261(3 Pt 1):G470–G475. doi: 10.1152/ajpgi.1991.261.3.G470. [DOI] [PubMed] [Google Scholar]
  119. Vane J. R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971 Jun 23;231(25):232–235. doi: 10.1038/newbio231232a0. [DOI] [PubMed] [Google Scholar]
  120. Vane J. Towards a better aspirin. Nature. 1994 Jan 20;367(6460):215–216. doi: 10.1038/367215a0. [DOI] [PubMed] [Google Scholar]
  121. Vio C. P., Cespedes C., Gallardo P., Masferrer J. L. Renal identification of cyclooxygenase-2 in a subset of thick ascending limb cells. Hypertension. 1997 Sep;30(3 Pt 2):687–692. doi: 10.1161/01.hyp.30.3.687. [DOI] [PubMed] [Google Scholar]
  122. Wallace J. L., Bak A., McKnight W., Asfaha S., Sharkey K. A., MacNaughton W. K. Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: implications for gastrointestinal toxicity. Gastroenterology. 1998 Jul;115(1):101–109. doi: 10.1016/s0016-5085(98)70370-1. [DOI] [PubMed] [Google Scholar]
  123. Wallace J. L., Keenan C. M., Granger D. N. Gastric ulceration induced by nonsteroidal anti-inflammatory drugs is a neutrophil-dependent process. Am J Physiol. 1990 Sep;259(3 Pt 1):G462–G467. doi: 10.1152/ajpgi.1990.259.3.G462. [DOI] [PubMed] [Google Scholar]
  124. Wallace J. L., McKnight W., Miyasaka M., Tamatani T., Paulson J., Anderson D. C., Granger D. N., Kubes P. Role of endothelial adhesion molecules in NSAID-induced gastric mucosal injury. Am J Physiol. 1993 Nov;265(5 Pt 1):G993–G998. doi: 10.1152/ajpgi.1993.265.5.G993. [DOI] [PubMed] [Google Scholar]
  125. Wallace J. L., McKnight W., Reuter B. K., Vergnolle N. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology. 2000 Sep;119(3):706–714. doi: 10.1053/gast.2000.16510. [DOI] [PubMed] [Google Scholar]
  126. Wallace J. L., Reuter B., Cicala C., McKnight W., Grisham M. B., Cirino G. Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat. Gastroenterology. 1994 Jul;107(1):173–179. doi: 10.1016/0016-5085(94)90074-4. [DOI] [PubMed] [Google Scholar]
  127. Wallace J. L., Tigley A. W. Review article: new insights into prostaglandins and mucosal defence. Aliment Pharmacol Ther. 1995 Jun;9(3):227–235. doi: 10.1111/j.1365-2036.1995.tb00377.x. [DOI] [PubMed] [Google Scholar]
  128. Wang J. Y., Yamasaki S., Takeuchi K., Okabe S. Delayed healing of acetic acid-induced gastric ulcers in rats by indomethacin. Gastroenterology. 1989 Feb;96(2 Pt 1):393–402. doi: 10.1016/0016-5085(89)91563-1. [DOI] [PubMed] [Google Scholar]
  129. Whittle B. J., Lopez-Belmonte J., Moncada S. Regulation of gastric mucosal integrity by endogenous nitric oxide: interactions with prostanoids and sensory neuropeptides in the rat. Br J Pharmacol. 1990 Mar;99(3):607–611. doi: 10.1111/j.1476-5381.1990.tb12977.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  130. Wright N. A., Pike C., Elia G. Induction of a novel epidermal growth factor-secreting cell lineage by mucosal ulceration in human gastrointestinal stem cells. Nature. 1990 Jan 4;343(6253):82–85. doi: 10.1038/343082a0. [DOI] [PubMed] [Google Scholar]
  131. Xie W. L., Chipman J. G., Robertson D. L., Erikson R. L., Simmons D. L. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci U S A. 1991 Apr 1;88(7):2692–2696. doi: 10.1073/pnas.88.7.2692. [DOI] [PMC free article] [PubMed] [Google Scholar]
  132. Yamagata K., Andreasson K. I., Kaufmann W. E., Barnes C. A., Worley P. F. Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron. 1993 Aug;11(2):371–386. doi: 10.1016/0896-6273(93)90192-t. [DOI] [PubMed] [Google Scholar]
  133. Yeomans N. D., Tulassay Z., Juhász L., Rácz I., Howard J. M., van Rensburg C. J., Swannell A. J., Hawkey C. J. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med. 1998 Mar 12;338(11):719–726. doi: 10.1056/NEJM199803123381104. [DOI] [PubMed] [Google Scholar]
  134. Zimmermann K. C., Sarbia M., Schrör K., Weber A. A. Constitutive cyclooxygenase-2 expression in healthy human and rabbit gastric mucosa. Mol Pharmacol. 1998 Sep;54(3):536–540. doi: 10.1124/mol.54.3.536. [DOI] [PubMed] [Google Scholar]
  135. de Witte T. J., Geerdink P. J., Lamers C. B., Boerbooms A. M., van der Korst J. K. Hypochlorhydria and hypergastrinaemia in rheumatoid arthritis. Ann Rheum Dis. 1979 Feb;38(1):14–17. doi: 10.1136/ard.38.1.14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  136. el-Omar E. M., Penman I. D., Ardill J. E., Chittajallu R. S., Howie C., McColl K. E. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology. 1995 Sep;109(3):681–691. doi: 10.1016/0016-5085(95)90374-7. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES